Fewer antibiotics during CAR-T therapy for lymphoma and myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two ways of giving antibiotics to people receiving CAR-T cell therapy for lymphoma or myeloma. It aims to find out whether a more limited antibiotic approach is just as safe and effective as the standard one, possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have either large B-cell lymphoma or multiple myeloma that has come back or not responded to treatment
- You are eligible for and planning to receive CAR-T cell therapy in Denmark
- You do not have an uncontrolled serious infection or severe colitis
- You are not allergic to cephalosporin or ciprofloxacin antibiotics
- You are not pregnant or breastfeeding, and you are able to understand and follow the trial rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special mix of gut bacteria can make CAR-T cell therapy work better for people with large B-cell lymphoma or multiple myeloma. You will take capsules of these bacteria before and during CAR-T treatment to see if it helps your body respond to the therapy.
This study compares two ways to help prevent infections after CAR-T cell therapy: regular antibody infusions (immunoglobulins) versus taking antibiotics. If you have low antibody levels after CAR-T treatment, this trial may help decide which approach works better for you.
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Hear when a new Gut Microbiota trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.